These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9650154)

  • 1. Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group.
    Koenig BA; Greely HT; McConnell LM; Silverberg HL; Raffin TA
    J Womens Health; 1998 Jun; 7(5):531-45. PubMed ID: 9650154
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
    Clark BA
    Cleve Clin J Med; 2000 Jun; 67(6):408-15,. PubMed ID: 10860223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma].
    Schmutzler RK; Kempe A; Kiechle M; Beckmann MW
    Dtsch Med Wochenschr; 1999 May; 124(18):563-6. PubMed ID: 10356583
    [No Abstract]   [Full Text] [Related]  

  • 5. Breast & ovarian cancer. Issues in risk assessment.
    Caro SW
    Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
    [No Abstract]   [Full Text] [Related]  

  • 6. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
    [No Abstract]   [Full Text] [Related]  

  • 7. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
    Rajagopal PS; Nielsen S; Olopade OI
    JAMA Netw Open; 2019 Aug; 2(8):e1910142. PubMed ID: 31434110
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic tests forge ahead, despite scientific concerns.
    Marshall A
    Nat Biotechnol; 1996 Dec; 14(13):1642-3. PubMed ID: 9634835
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of BRCA1 genetic testing.
    Dørum A; Heimdal K; Møller P
    Acta Obstet Gynecol Scand; 1998 Apr; 77(4):458-61. PubMed ID: 9598958
    [No Abstract]   [Full Text] [Related]  

  • 11. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
    Randall TC; Bell KA; Rebane BA; Rubin SC; Boyd J
    Gynecol Oncol; 1998 Sep; 70(3):432-4. PubMed ID: 9790802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic counseling for BRCA1/BRCA2 testing.
    Schneider KA
    Genet Test; 1997; 1(2):91-8. PubMed ID: 10464632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical aspects of genetic counseling in familial breast and ovarian cancer. Combining applied theory and reflective practice.
    Goelen G; Rigo A; Neyns B; Betz W; De Grève J
    Ann N Y Acad Sci; 1997 Dec; 833():170-2. PubMed ID: 9616750
    [No Abstract]   [Full Text] [Related]  

  • 15. Coming to grips with genes and risk.
    Kahn P
    Science; 1996 Oct; 274(5287):496-8. PubMed ID: 8928001
    [No Abstract]   [Full Text] [Related]  

  • 16. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.
    Heisey RE; Carroll JC; Warner E; McCready DR; Goel V
    Can Fam Physician; 1999 Jan; 45():114-24. PubMed ID: 10889864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing.
    Lerman C; Hughes C; Lemon SJ; Main D; Snyder C; Durham C; Narod S; Lynch HT
    J Clin Oncol; 1998 May; 16(5):1650-4. PubMed ID: 9586874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A public health perspective on the control of predictive screening for breast cancer.
    Cunningham GC
    Health Matrix Clevel; 1997; 7(1):31-48. PubMed ID: 10167177
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.